Novartis, CH0012005267

Novartis stock gets a higher FY2027 EPS forecast

Published on 09/28/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock faces a revised FY2027 EPS view after Zacks Research lifted its estimate to USD 9.75 on September 25, 2026. Q2 sales reached USD 14.41 billion.

Pop-Art-Illustration einer DNA-Doppelhelix mit Kapsel in leuchtendem Halftone-Raster — Novartis AG CH0012005267 – Pop-Art-Comic mit stilisierter DNA-Helix und Kapsel im bunten Halftone-Raster, Illustration mit AI erstellt.

Novartis stock (ISIN CH0012005267) closed at CHF 119.80 on SIX on September 25, 2026, while a new FY2027 earnings estimate puts the focus on profit growth. According to MarketBeat, Zacks Research raised its FY2027 EPS estimate to USD 9.75 from USD 9.68 in a report issued on September 25, 2026.

Higher EPS forecast sets the tone

The increase is measured against a current full-year consensus estimate of USD 8.87, according to MarketBeat. Zacks also projected USD 2.47 in EPS for the fourth quarter of 2027, giving the forecast a longer-term earnings dimension.

The latest reported quarter supplies the operating benchmark. Investing.com lists Q2 2026 revenue at USD 14.41 billion and EPS at USD 2.41, reported on July 21, 2026. Novartis investor materials identify the same date as the publication date for its second-quarter results.

Analyst targets remain divided

Goldman Sachs retained a Sell rating and cut its Novartis price target to CHF 110.00 from CHF 113.00 on September 22, 2026, according to MarketScreener. The target sits below the September 25 closing price, contrasting with the higher earnings estimate from Zacks Research.

The next scheduled earnings release is October 26, 2026, according to MarketScreener. That date gives investors a defined checkpoint for testing whether the revised earnings view is translating into operating progress.

Stock stays below its yearly high

Novartis stock closed at CHF 119.80 on SIX on September 25, 2026. The session data showed a 52-week range of CHF 97.05 to CHF 132.68, a market capitalization of CHF 227.7 billion and volume of 3,350,000 shares.